Last edition
News about "US pharmaceutical market"
US FDA Approves Lupin's Generic Diazepam Injection in Prefilled Syringe Format
Lupin has secured US FDA approval for its generic diazepam injection USP in a single-dose prefilled syringe format. The bioequivalent version of Roche's Valium injection expands the company's US injectable portfolio and addresses a market valued at nearly USD 78 million annually.
US Pharmaceutical Market | 04/08/2026 | By News Bureau
Lupin Launches Generic Sugammadex Injection in the US Following FDA Approval
Lupin launches Sugammadex Injection in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The bioequivalent version of Merck's Bridion Injection is indicated for reversing neuromuscular blockade in adult and paediatric patients aged two years and older undergoing surgery.
US Pharmaceutical Market | 31/07/2026 | By News Bureau
Aurobindo Pharma USA Completes Acquisition of Lannett Company
Aurobindo Pharma USA has completed the acquisition of Lannett Company after securing approval from the US Federal Trade Commission. Effective June 29, 2026, Lannett will operate as Lannett Company LLC, with the combined entity aiming to strengthen the supply of essential medicines and enhance value for patients and customers.
US Pharmaceutical Market | 30/06/2026 | By News Bureau
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400 mg
Dr. Reddy’s has launched Bosutinib Tablets 400 mg in the US, becoming the first generic equivalent of Bosulif available in the market.
US Pharmaceutical Market | 15/06/2026 | By News Bureau
Lupin Launches Diabetes Drug Combination in the US
Lupin launches dapagliflozin and metformin extended-release tablets in the US, offering a bioequivalent and cost-effective alternative for type 2 diabetes management.
US Pharmaceutical Market | 22/04/2026 | By News Bureau | 157
Glenmark Takes Charge of RYALTRIS Commercialisation in US
Glenmark will handle end-to-end commercialisation and distribution of RYALTRIS nasal spray in the US, strengthening its respiratory portfolio presence.
US Pharmaceutical Market | 06/04/2026 | By News Bureau | 320
Alembic Pharmaceuticals reports first prescription sale of Pivya in the US, marking its entry into the branded pharmaceutical segment with a first-line oral antibiotic for uncomplicated urinary tract infections in women.
US Pharmaceutical Market | 07/03/2026 | By News Bureau | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy